The Food and Drug Administration today released briefing documents for tomorrow’s convening of the agency’s Vaccines and Related Biological Products Advisory Committee, which will consider COVID-19 vaccine booster shot applications from Moderna and Johnson & Johnson. One notable aspect of J&J’s application is the drug maker’s request that FDA approve a booster shot program that would vary the timing of the booster’s administration based on patients’ individual circumstances. Such circumstances include individuals’ risk level related to their health or employment. For example, J&J recommends a booster two months after the first dose for high-risk individuals, including health care providers and front-line workers at high risk of exposure, severely immunocompromised people and those with certain underlying conditions who may not have mounted a sufficient immune response to one dose. Other so-called “low-risk” individuals might be recommended for a booster six months after their initial dose.
 
Moderna, meanwhile, suggests that a 50-microgram booster dose of its vaccine yielded a comparable immune response to a 100-microgram dose; in doing so, the potential for adverse reactions was limited.
 
In addition to the Moderna and J&J booster discussions, the committee will review National Institutes of Health data on mix-and-match booster doses, in which people who were initially immunized with one brand's vaccine could get another manufacturer's booster.

 

Related News Articles

Headline
In a study of symptomatic adults tested for SARS-CoV-2 at U.S. pharmacies since Sept. 14, bivalent COVID-19 vaccine boosters provided additional protection…
Headline
The Biden Administration today launched a six-week campaign to encourage Americans to get an updated COVID-19 vaccine. In addition to ongoing pop-up clinics,…
Headline
Children under age 5 are more likely to receive a COVID-19 vaccine if their parents perceive it as safe and their health care provider recommends it, according…
Headline
AHA this week released a new Thanksgiving-focused toolkit to help promote pediatric COVID-19 vaccination on social media, including sample content and graphics…
Headline
The Food and Drug Administration recently updated its health care provider fact sheet on bebtelovimab to note that the monoclonal antibody is not expected…
Headline
Black patients who sought outpatient care for COVID-19 between January and July 2022 were 36% less likely than white patients to receive the antiviral pill…